Published Date: 04 Mar 2023
Karnataka: Karnataka Examination Authority (KEA) yog PG AYUSH ...
Read Full NewsTopline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.
Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.
Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.
FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy
AI Tools Fall Short for Dietary Recommendations for Managing IBS
Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo
Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs
1.
New drug combination shows good results in patients with HPV-negative head and neck cancer
2.
A new drug delivery system may help patients with a rare eye cancer
3.
C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.
4.
What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care
5.
Prostate cancer death risk is higher in late teens and early 20s weight gain.
1.
Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options
2.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
3.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
4.
Anemia in Older Adults: Causes, Clinical Impact, and Evidence-Based Management
5.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation